Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study
Source: View publication →
In patients with unfavorable cancer of unknown primary who achieved disease control after induction chemotherapy, comprehensive genomic profiling followed by molecularly guided therapy significantly improved progression-free survival compared to continued platinum-based chemotherapy.
Key Findings
Study Design
Study Limitations
Clinical Significance
The CUPISCO trial provides the first prospective, randomized evidence that a biomarker-driven precision oncology framework can alter the natural history of unfavorable cancer of unknown primary (CUP). By demonstrating that comprehensive genomic profiling (CGP) successfully matches patients to targeted therapies that outperform empiric chemotherapy, it establishes early CGP and subsequent molecularly guided therapy as a new standard of care for this historically intractable disease.
Historical Context
Cancer of unknown primary (CUP) has historically accounted for 2-5% of all newly diagnosed malignancies and carries a notoriously dismal prognosis, especially in the 'unfavorable' subset. For decades, standard treatment relied on empiric, broad-spectrum platinum-based chemotherapy. Earlier attempts to improve outcomes by using tissue-of-origin gene expression profiling to direct site-specific therapies (such as in the GEFCAPI 04 trial) failed to demonstrate superiority over standard chemotherapy. CUPISCO represents a paradigm shift, proving that instead of attempting to predict the tissue of origin, directly matching comprehensive genomic alterations to targeted treatments yields superior clinical outcomes.
Guided Discussion
High-yield insights from every perspective
How does the biological concept of cancer of unknown primary (CUP) differ from traditional metastasis, and why does comprehensive genomic profiling (CGP) provide a more rational therapeutic target than site-specific histology in unfavorable CUP?
Key Response
CUP represents a heterogeneous group of metastatic tumors where the primary site cannot be identified. Traditional oncology targets the tissue of origin. Since unfavorable CUP lacks a known origin and has a poor prognosis with empiric chemotherapy, CGP shifts the paradigm to treating the specific molecular driver (e.g., BRAF, ERBB2 mutations) rather than the anatomical origin, illustrating the shift to agnostic precision oncology.
The CUPISCO trial required patients to achieve disease control with 3 cycles of induction chemotherapy before randomization to molecularly guided therapy. Clinically, why is initial empiric platinum-based chemotherapy still standard before transitioning to targeted therapy in these patients?
Key Response
In unfavorable CUP, patients often present with rapidly progressing, symptomatic disease. Waiting for comprehensive genomic profiling results can take weeks, risking rapid clinical deterioration. Initial empiric platinum-based chemotherapy serves to gain rapid disease control, buying time for molecular profiling and ensuring patients are fit enough for targeted therapy once results return.
Given that comprehensive genomic profiling in CUPISCO was likely performed on tissue obtained before induction chemotherapy, how might clonal evolution and tumor heterogeneity induced by platinum-based chemotherapy impact the efficacy of the subsequent molecularly guided therapy?
Key Response
Platinum chemotherapy induces DNA damage and selective pressure, potentially leading to clonal evolution or resistance mutations. If targeted therapy is chosen based on pre-chemotherapy biopsy results, the dominant molecular driver may have shifted. Fellows must consider whether repeat biopsies or circulating tumor DNA (ctDNA) analysis at randomization might better reflect the current actionable genomic landscape.
While CUPISCO demonstrates a PFS benefit for MGT in unfavorable CUP after induction chemotherapy, how should we balance the high cost and access barriers of comprehensive genomic profiling and off-label targeted therapies with the modest survival gains in real-world practice?
Key Response
The transition from trial to practice requires pragmatism. Attendings must weigh the statistical significance of PFS against absolute clinical benefit, financial toxicity, and logistical hurdles of insurance approval. A key teaching point is that actionable mutations do not guarantee dramatic responses, requiring shared decision-making regarding quality of life versus pursuing every molecular target.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The CUPISCO trial utilized an open-label, randomized phase 2 design with progression-free survival (PFS) as the primary endpoint. From a methodological standpoint, how does the open-label nature introduce bias in assessing PFS, and what statistical methods could robustly validate PFS as a surrogate for overall survival in this highly heterogeneous population?
Key Response
Open-label designs are prone to assessment bias, as knowledge of the treatment arm can influence scan interpretation or timing of progression, making blinded independent central review critical. Furthermore, validating PFS as a surrogate for OS in CUP is statistically challenging due to molecular heterogeneity and post-progression crossover, requiring trial-level meta-regression or copula-based models to establish true correlation.
The MGT arm in CUPISCO is essentially a basket of different targeted therapies tailored to individual genomic alterations. As an editor, how do you critically appraise a trial where the intervention arm is a heterogeneous strategy, and what specific supplementary data must be demanded?
Key Response
A major threat to validity in strategy trials is that a statistically significant overall benefit might be driven by a small subset of patients (e.g., those with BRAF or NTRK alterations) who have exceptional responses. An editor must demand detailed forest plots of PFS by specific molecular pathway and agent to determine if the strategy is universally beneficial or merely masking a few highly effective outlier treatments.
Current ESMO and NCCN guidelines recommend empiric platinum-based chemotherapy for unfavorable CUP and suggest comprehensive genomic profiling primarily for trial eligibility. Based on the CUPISCO phase 2 results, is there sufficient evidence to upgrade the recommendation for CGP and subsequent molecularly guided therapy to a standard-of-care Level I recommendation?
Key Response
While CUPISCO provides strong prospective Phase 2 data (Level II evidence) that MGT improves PFS over maintenance chemotherapy, guideline committees typically require Phase 3 data with an Overall Survival benefit for a Level I recommendation. The committee would likely upgrade CGP to a strongly recommended tier (e.g., NCCN Category 2A) to guide maintenance but may hesitate to make it an absolute standard without definitive OS data and cost-effectiveness analyses.
Clinical Landscape
Noteworthy Related Trials
SHIVA Trial
Tested
Molecularly targeted therapy based on tumor profiling
Population
Patients with advanced cancer refractory to standard care
Comparator
Treatment at physician's choice
Endpoint
Progression-free survival
WJTOG1201 Trial
Tested
Site-specific therapy dictated by gene expression profiling
Population
Patients with untreated unfavorable carcinoma of unknown primary
Comparator
Empirical chemotherapy (Paclitaxel and Carboplatin)
Endpoint
1-year survival rate
NCI-MATCH Trial
Tested
Targeted therapies matched to specific actionable genetic mutations
Population
Patients with relapsed or refractory solid tumors and lymphomas
Comparator
Historical controls (Phase 2 basket trial design)
Endpoint
Objective response rate
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis